<SEC-DOCUMENT>0001193125-21-026783.txt : 20210203
<SEC-HEADER>0001193125-21-026783.hdr.sgml : 20210203
<ACCEPTANCE-DATETIME>20210203113058
ACCESSION NUMBER:		0001193125-21-026783
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210203
DATE AS OF CHANGE:		20210203

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vor Biopharma Inc.
		CENTRAL INDEX KEY:			0001817229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-252175
		FILM NUMBER:		21584970

	BUSINESS ADDRESS:	
		STREET 1:		215 FIRST STREET
		STREET 2:		SUITE 430
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-655-6580

	MAIL ADDRESS:	
		STREET 1:		215 FIRST STREET
		STREET 2:		SUITE 430
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vor Biopharma Inc.
		CENTRAL INDEX KEY:			0001817229
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		215 FIRST STREET
		STREET 2:		SUITE 430
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-655-6580

	MAIL ADDRESS:	
		STREET 1:		215 FIRST STREET
		STREET 2:		SUITE 430
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>d39632dfwp.htm
<DESCRIPTION>FWP
<TEXT>
<HTML><HEAD>
<TITLE>FWP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 433 under the Securities Act of 1933 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Issuer Free Writing Prospectus dated February&nbsp;3, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Relating to Preliminary Prospectus issued February&nbsp;3, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-252175</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g39632g0203122522750.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This free writing prospectus relates to the initial public offering of shares of common stock of Vor Biopharma Inc. (the
&#147;Company&#148;). On February&nbsp;3, 2021, the Company filed with the U.S. Securities and Exchange Commission (the &#147;SEC&#148;) Amendment No.&nbsp;2 to its Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT>
(Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-252175)</FONT> relating to its initial public offering (&#147;Amendment No.&nbsp;2&#148;). Amendment No.&nbsp;2 updates and supplements certain information set forth in Amendment No.&nbsp;1
to the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> filed with the SEC on February&nbsp;1, 2021 (&#147;Amendment No.&nbsp;
1&#148;). Amendment No. 2 can be accessed through the following link: <A HREF="http://www.sec.gov/Archives/edgar/data/1817229/000119312521026728/d942530ds1a.htm">https://www.sec.gov/Archives/edgar/data/1817229/000119312521026728/d942530ds1a.htm</A>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This free writing prospectus should be read together with Amendment No.&nbsp;2 to the Registration Statement, including the preliminary prospectus
contained therein, especially the &#147;Risk Factors&#148; section and the financial statements and related notes, before deciding to invest in these securities. Unless the context otherwise requires, the terms &#147;we,&#148; &#147;us&#148; and
&#147;our&#148; in this free writing prospectus refer to Vor Biopharma Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth below are the updates and supplements contained in Amendment
No.&nbsp;2 relative to Amendment No.&nbsp;1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Risk Factors (page 21) </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are substantially dependent on the success of our two most advanced product candidates, VOR33 and VCAR33. If we are unable to complete development of,
obtain approval for and commercialize VOR33 or VCAR33 in a timely manner, our business will be harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future success is
dependent on our ability to timely advance and complete clinical trials, obtain marketing approval for and successfully commercialize our product candidates VOR33 and VCAR33. We are investing significant efforts and financial resources in the
research and development of these product candidates. Our IND application for VOR33 in combination with Mylotarg in patients with AML was submitted to the FDA in December 2020 and took effect in January 2021, and we expect to initiate a Phase 1/2a
clinical trial of VOR33 in the first half of 2021. VCAR33 is also undergoing a multi-site, investigator-initiated Phase 1/2 clinical trial in relapsed AML patients as a monotherapy in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;bridge-to-transplant&nbsp;setting.</FONT></FONT> The VCAR33 trial is currently sponsored and overseen by the National Marrow Donor Program (NMDP), however, we expect to either
assume sponsorship and oversight of the trial prior to its completion or enter into an agreement with the NMDP providing us with the right to cross-reference the trial results in future IND applications that we may submit to the FDA. VOR33 and
VCAR33 will each require additional clinical development, evaluation of clinical, preclinical and manufacturing activities, marketing approval from government regulators, substantial investment and significant marketing efforts before we can
generate any revenues from product sales. We are not permitted to market or promote VOR33, VCAR33 or any other product candidate, before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never
receive such marketing approvals. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The success of VOR33 and VCAR33 will depend on several factors, including the following:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the acceptance by the FDA of our IND application to allow us to proceed with a clinical trial of VOR33 in combination with Mylotarg for the treatment of patients with AML who are at high risk for relapse;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the acceptance of individual investigational review boards (IRBs) and scientific review committees at each clinical trial site as to the adequacy of the preclinical data package to support clinical development of VOR33 and their
overall general agreement with the use of VOR33 in the intended patient population in the intended manner;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the willingness of clinical investigators to place patients in the clinical trials, and the willingness of patients to enroll in a clinical trial studying
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;first-in-human&nbsp;cell</FONT></FONT> therapy;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the successful and timely completion of our planned Phase 1/2a clinical trial of VOR33 and the ongoing Phase 1/2 clinical trial of VCAR33;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">our ability to incorporate the results of the ongoing Phase 1/2 clinical trial of VCAR33 for the treatment of AML into future regulatory filings, either as a result of the timely transfer to us by the NMDP of the related IND or
obtaining cross-reference rights to those trial results;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the initiation and successful patient enrollment and completion of additional clinical trials of VOR33 and VCAR33 on a timely basis;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">maintaining and establishing relationships with contract research organizations (CROs) and clinical sites for the clinical development of VOR33 and VCAR33 both in the United States and internationally;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the frequency and severity of adverse events in the clinical trials;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the results of clinical trials conducted by third parties in hematopoietic stem cell transplant (HSCT) if such trials result in changes to the standard of care for HSCT or otherwise cause us to change our clinical trial protocols;
for example, the National Heart, Lung, and Blood Institute (NHLBI), in collaboration with the Blood and Marrow Transplant Clinical Trials Network and the National Cancer Institute, is sponsoring a Phase 3 clinical trial of the use in HSCT of CD34
selected T cell depleted HSCs (CD34 HSCs), which are the same types of cells used in manufacturing VOR33, in patients with acute leukemia or myelodysplasia, and if the data from this trial suggests that these cells are inferior to the standard of
care, our planned Phase 1/2a clinical trial of VOR33 could be significantly delayed;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the efficacy, safety and tolerability profiles that are satisfactory to the FDA, EMA or any comparable foreign regulatory authority for marketing approval;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the timely receipt of marketing approvals for VOR33 and VCAR33 from applicable regulatory authorities;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the extent of any required post-marketing approval commitments to applicable regulatory authorities;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the maintenance of existing or the establishment of new supply arrangements with third-party suppliers and manufacturers for clinical development of VOR33 and VCAR33;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the maintenance of existing, or the establishment of new, scaled production arrangements with third-party manufacturers to obtain finished products that are appropriate for commercial sale of VOR33 and VCAR33, if either is
approved;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the protection of our rights in our intellectual property portfolio;</TD></TR></TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="98%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="98%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">the successful launch of commercial sales following any marketing approval;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">a continued acceptable safety profile following any marketing approval;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">commercial acceptance by patients, the medical community and third-party payors;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">our ability to obtain coverage and adequate reimbursement from third-party payors for our products and patients&#146; willingness to
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay&nbsp;out-of-pocket&nbsp;in</FONT></FONT> the absence of such coverage and adequate reimbursement; and</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#149;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">our ability to compete with other treatments.</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the NHLBI trial above, on February&nbsp;2, 2021, we became aware of an abstract
summarizing preliminary results of the trial, which are scheduled to be presented orally at a scientific conference on February&nbsp;12, 2021. According to the abstract, the NHLBI trial did not observe a statistically significant difference between
the CD34 HSC grafts and the bone marrow grafts that served as a comparison with respect to the primary endpoint of graft versus host disease (GVHD) (moderate/severe) relapse-free survival at 12 months. There was a statistically significantly lower
incidence of chronic GVHD in the CD34 HSC arm of the trial. There was also a statistically significantly higher incidence of treatment related mortality (TRM) in the CD34 HSC arm, contributing to poorer overall survival compared to the bone marrow
arms. Additional details about TRM in the trial were not disclosed in the abstract. Due to our current lack of additional information regarding the TRM observed in the trial, including the cause or causes, we are unable to evaluate the significance
of these trial results for our own manufacturing process or clinical development plan for VOR33. If and as we learn more about the results of the NHLBI trial, we may decide that the manufacturing process or clinical trial protocol for VOR33 merit
changes in response to this new information. Any amendments to our clinical trial protocol to accommodate these changes would introduce delays into our current clinical development timeline, including delays in initiating our first-in-human clinical
trial of VOR33. Additional results from this third party trial may also result in enrollment delays. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have complete control over
many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future
collaborator. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize VOR33 and/or VCAR33, which would materially harm
our business. If we do not receive marketing approvals for VOR33 and VCAR33 we may not be able to continue our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Commencing
clinical trials in the United States for VOR33 is subject to acceptance by the FDA of our IND for this program and finalizing the trial design based on discussions with the FDA and other regulatory authorities. In the event that the FDA requires us
to complete additional preclinical studies or we are required to satisfy other FDA requests, the start of our first clinical trial for VOR33 may be delayed. Even after we receive and incorporate guidance from these regulatory authorities, the FDA or
other regulatory authorities could disagree that we have satisfied their requirements to commence our clinical trial or change their position on the acceptability of our trial design or the clinical endpoints selected, which may require us to
complete additional preclinical studies or clinical trials or impose stricter approval conditions than we currently expect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Business (page 130) </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the components of our current manufacturing protocol for VOR33 is the use of CD34-selected T cell-depleted HSCs (CD34 HSCs) as grafts in
the HSCT process. The National Heart, Lung, and Blood Institute (NHLBI), in collaboration with the Blood and Marrow Transplant Clinical Trials Network and the National Cancer Institute, is currently sponsoring a Phase 3 clinical trial in patients
with acute leukemia or myelodysplasia evaluating the use of CD34 HSC grafts in HSCT in comparison to bone marrow grafts. The trial included 104 patients in the CD34 HSC arm (of whom only 89 received per protocol therapy) and 232 patients in the bone
marrow graft arms. The primary endpoint of the trial was chronic graft versus host disease (GVHD) (moderate/severe) relapse-free survival at 12 months, with secondary endpoints of overall survival, GVHD, relapse-free survival, relapse and
transplant-related mortality (TRM), which is a general categorization of deaths related to the transplant that do not result from relapse. On February 2, 2021, we became aware of an abstract summarizing preliminary results of the NHLBI&#146;s trial,
which are scheduled to be presented orally at a scientific conference on February 12, 2021. According to the abstract, the NHLBI trial did not observe a statistically significant difference between the CD34 HSC grafts and the bone marrow grafts with
respect to the primary endpoint. There was a statistically significantly lower incidence of chronic GVHD in the CD34 HSC arm of the trial, indicating that grafts lacking in T cells were less likely to be associated with these negative immune
reactions in transplant recipients. There was also a statistically significantly higher incidence of TRM in the CD34 HSC arm, contributing to poorer overall survival compared to the other arms. Additional details about TRM in the trial were not
disclosed in the abstract. TRM can result from a number of different causes and TRM results in the trial could have been confounded by a variety of factors, including the use of different donor sources, conditioning regimens and the original treated
disease, as well as non-compliance within each arm with respect to donor collection. Due to our current lack of additional information regarding the TRM observed in the trial, including the cause or causes, we are unable to evaluate the significance
of these trial results for our own clinical development plan for VOR33. If and as we learn more about the results of the NHLBI trial, we may decide that the clinical trial protocol or manufacturing process for VOR33 merit changes in response to this
new information. Any amendments to our manufacturing process or clinical trial protocol to accommodate these changes would introduce delays into our current clinical development timeline, including delays in initiating our first-in-human clinical
trial of VOR33. Additional results from this third party trial may also result in enrollment delays. We do not believe the results of the NHLBI trial undermine the fundamental scientific premise of VOR33 nor do we believe these results adversely
impact the overall viability of the VOR33 program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Company has filed a registration statement, including a preliminary prospectus, with the U.S.
Securities and Exchange Commission (the &#147;SEC&#148;) for the offering to which this communication relates. Before you invest, you should read the preliminary prospectus in that registration statement and other documents we have filed with the
SEC for more complete information about us and the Offering. You may get these documents for free by visiting EDGAR on the SEC web site at www.sec.gov. Alternatively, a copy of the preliminary prospectus may be obtained from Goldman Sachs&nbsp;&amp;
Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-866-471-2526,</FONT></FONT></FONT> or via
email at <FONT STYLE="white-space:nowrap">prospectus-ny@ny.email.gs.com;</FONT> Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, via telephone at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-888-474-0200,</FONT></FONT></FONT> or via email at ecm.prospectus@evercore.com; Barclays Capital Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New
York 11717, via telephone at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-888-603-5847,</FONT></FONT></FONT> or via email at Barclaysprospectus@broadridge.com; or Stifel, Nicolaus&nbsp;&amp;
Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, via telephone at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-415-364-2720,</FONT></FONT></FONT> or via email at syndprospectus@stifel.com. </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g39632g0203122522750.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g39632g0203122522750.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "  6,# 2(  A$! Q$!_\0
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M !1110 4444 <I\0[?SO"<KX_P!1*DGZ[?\ V:O'Z]V\2V_VKPSJ,6,G[.S
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M %(0&4JP!!&"#WI:* /!O'/AXZ#KS^6I^R7&9(CZ>H_"N8KZ!\8: GB#0I8
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MT@)J&IJLM]U2/JL/^+?RKNZ**\Z<W-W904445(!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
%110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
